164650-68-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-5-methoxybenzaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-chloro-5-methoxybenzaldehyde is employed as an intermediate for the production of agrochemicals, contributing to the development of effective pest control agents and other agricultural products.
Used in Dye Production:
3-Chloro-5-methoxybenzaldehyde is used as a building block in the production of dyes, enabling the creation of a wide range of colorants for various applications, including textiles, plastics, and printing inks.
Used in Fine Chemicals Industry:
3-CHLORO-5-METHOXYBENZALDEHYDE is also utilized in the synthesis of other fine chemicals, where its unique properties can be leveraged to produce specialty chemicals for various industrial applications.
Used in Medicinal Chemistry Research:
3-Chloro-5-methoxybenzaldehyde is used in research for its potential antibacterial and antimicrobial properties, making it a valuable compound for the development of new antimicrobial agents to combat drug-resistant infections.

Upstream product

• 33719-74-3 3,5-dichloroanisole 
• 106-93-4 ethylene dibromide 
• 82477-68-7 (3-chloro-5-methoxyphenyl)methanol 
• 68-12-2 N,N-dimethyl-formamide 
• 1984-59-4 2,3-dichloroanisole 

Downstream Products

• 945002-70-0 6-(3-chloro-5-methoxyphenyl)-4-hydroxy-2-methylthiopyrimidine-5-carbonitrile 
• 945001-66-1 C₁₅H₁₃ClN₄O₂ 
• 82477-68-7 (3-chloro-5-methoxyphenyl)methanol 
• 1386975-89-8 1-[3-(3-chloro-5-methoxy-benzylamino)propyl]-3-(thiophen-3-yl)urea 
• 1386975-66-1 C₁₈H₂₂ClN₃O₂ 
• 1829-33-0 3-chloro-5-hydroxybenzaldehyde 

Relevant academic research and scientific papers

Inhibitors of Serine Proteases

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

IN VIVO IMAGING COMPOUNDS

The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor. [image]

INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.

INHIBITORS OF SERINE PROTEASES

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION

According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen

MODIFIED RELEASE PHARMACEUTICAL FORMULATION

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS

There is provided compounds of formula I, wherein R 1, R 2, R 3, R x, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required as in thrombosis or as anticoagulants.